Interleukin-17A exacerbates disease severity in BALB/c mice susceptible to lung infection with Mycoplasma pulmonis

Infection and Immunity

Volumn 86, Issue 9, 2018, Pages

  Mize, Maximillion T ^a   Sun, Xiangle L ^a   Simecka, Jerry W ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Bacterial; Cytokines; IL 17; Inflammation; Lung infection; Mucosa; Mycoplasma; Th17 cells

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; GAMMA INTERFERON; IL17A PROTEIN, MOUSE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; LUNG INFECTION; LUNG INFILTRATE; MOUSE; MYCOPLASMA PULMONIS; MYCOPLASMOSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CD4+ T LYMPHOCYTE; IMMUNOLOGY; LUNG; MICROBIOLOGY; PATHOLOGY; RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-17; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOPLASMA INFECTIONS; MYCOPLASMA PULMONIS; NEUTROPHILS; RESPIRATORY TRACT INFECTIONS;

EID: 85052757614     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00292-18     Document Type: Article

References (71)

1. Narita M. 2009. Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection. Pediatr Neurol 41:159-166. https://doi.org/10.1016/j.pediatrneurol.2009.04.012
2. Khan FY, Ay M. 2009. Mycoplasma pneumoniae associated with severe autoimmune hemolytic anemia: case report and literature review. Braz J Infect Dis 13:77-79. https://doi.org/10.1590/S1413-86702009000100018
3. Foy HM. 1993. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 17(Suppl 1):S37-S46. https://doi.org/10.1093/clinids/17.Supplement_1.S37
4. Simecka JW, Davis JK, Davidson MK, Ross SE, Stadtlander C, Cassell GH. 1992. Mycoplasma diseases of animals, p 391-415. In Maniloff J, McElhaney RN, Finch LR, Baseman JB (ed), Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, DC
5. Kraft M, Hamid Q. 2006. Mycoplasma in severe asthma. J Allergy Clin Immunol 117:1197-1198. https://doi.org/10.1016/j.jaci.2006.03.001
6. Gray GC, Duffy LB, Paver RJ, Putnam SD, Reynolds RJ, Cassell GH. 1997. Mycoplasma pneumoniae: a frequent cause of pneumonia among U.S. Marines in southern California. Mil Med 162:524-526
7. Gelfand EW. 1993. Unique susceptibility of patients with antibody deficiency to mycoplasma infection. Clin Infect Dis 17(Suppl 1):S250-S253
8. Park SJ, Pai KS, Kim AR, Lee JH, Shin JI, Lee SY. 2012. Fulminant and fatal multiple organ failure in a 12-year-old boy with Mycoplasma pneumoniae infection. Allergy Asthma Immunol Res 4:55-57. https://doi.org/ 10.4168/aair.2012.4.1.55
9. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka M, Kenri T, Arakawa Y, Sasaki T. 2006. Clinical evaluation of macrolideresistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 50: 709-712. https://doi.org/10.1128/AAC.50.2.709-712.2006
10. Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, Ebihara T, Ubukata K, Sato Y, Akita H, Sunakawa K, Iwata S. 2009. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother 15:380-383. https://doi.org/10.1007/ s10156-009-0715-7
11. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubukata K, Acute Respiratory Diseases Study Group. 2008. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 52:348-350. https://doi.org/10.1128/AAC.00779-07
12. Shimizu T, Kimura Y, Kida Y, Kuwano K, Tachibana M, Hashino M, Watarai M. 2014. Cytadherence of Mycoplasma pneumoniae induces inflammatory responses through autophagy and Toll-like receptor 4. Infect Immun 82:3076-3086. https://doi.org/10.1128/IAI.01961-14
13. Yamamoto T, Kida Y, Sakamoto Y, Kuwano K. March 2017. Mpn491, a secreted nuclease of Mycoplasma pneumoniae, plays a critical role in evading killing by neutrophil extracellular traps. Cell Microbiol 19. https://doi.org/10.1111/cmi.12666
14. Kannan TR, Coalson JJ, Cagle M, Musatovova O, Hardy RD, Baseman JB. 2011. Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model. J Infect Dis 204:1596-1604. https://doi.org/10.1093/infdis/jir557
15. Simecka JW, Davis JK, Cassell GH. 1987. Specific vs. nonspecific immune responses in murine respiratory mycoplasmosis. Isr J Med Sci 23:485-489
16. Dobbs NA, Zhou X, Pulse M, Hodge LM, Schoeb TR, Simecka JW. 2014. Antigen-pulsed bone marrow-derived and pulmonary dendritic cells promote Th2 cell responses and immunopathology in lungs during the pathogenesis of murine mycoplasma pneumonia. J Immunol 193: 1353-1363. https://doi.org/10.4049/jimmunol.1301772
17. Bodhankar S, Woolard MD, Sun X, Simecka JW. 2009. NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization. J Immunol 183: 2622-2631. https://doi.org/10.4049/jimmunol.0802180
18. Mogabgab WJ, Marchand S, Mills G, Beville R. 1975. Efficacy of inactivated Mycoplasma pneumoniae vaccine in man. Dev Biol Stand 28: 597-608
19. Cassell GH. 1982. Derrick Edward Award Lecture. The pathogenic potential of mycoplasmas: Mycoplasma pulmonis as a model. Rev Infect Dis 4(Suppl):S18-S34
20. Cassell GH, Cole BC. 1981. Mycoplasmas as agents of human disease. N Engl J Med 304:80-89. https://doi.org/10.1056/NEJM198101083040204
21. Lindsey JR, Cassell H. 1973. Experimental Mycoplasma pulmonis infection in pathogen-free mice. Models for studying mycoplasmosis of the respiratory tract. Am J Pathol 72:63-90
22. Cartner SC, Lindsey JR, Gibbs-Erwin J, Cassell GH, Simecka JW. 1998. Roles of innate and adaptive immunity in respiratory mycoplasmosis. Infect Immun 66:3485-3491
23. Jones HP, Simecka JW. 2003. T lymphocyte responses are critical determinants in the pathogenesis and resistance to Mycoplasma respiratory disease. Front Biosci 8:d930-d945. https://doi.org/10.2741/1098
24. Jones HP, Tabor L, Sun X, Woolard MD, Simecka JW. 2002. Depletion of CD8+ T cells exacerbates CD4+ Th cell-associated inflammatory lesions during murine mycoplasma respiratory disease. J Immunol 168: 3493-3501. https://doi.org/10.4049/jimmunol.168.7.3493
25. Odeh AN, Simecka JW. 2016. Regulatory CD4+CD25+ T cells dampen inflammatory disease in murine mycoplasma pneumonia and promote IL-17 and IFN-gamma responses. PLoS One 11:e0155648. https://doi.org/ 10.1371/journal.pone.0155648
26. Dobbs NA, Odeh AN, Sun X, Simecka JW. 2009. The multifaceted role of T cell-mediated immunity in pathogenesis and resistance to Mycoplasma respiratory disease. Curr Trends Immunol 10:1-19
27. Woolard MD, Hodge LM, Jones HP, Schoeb TR, Simecka JW. 2004. The upper and lower respiratory tracts differ in their requirement of IFN-gamma and IL-4 in controlling respiratory mycoplasma infection and disease. J Immunol 172:6875-6883. https://doi.org/10.4049/ jimmunol.172.11.6875
28. Nicholas RA, Ayling RD, Stipkovits LP. 2002. An experimental vaccine for calf pneumonia caused by Mycoplasma bovis: clinical, cultural, serological and pathological findings. Vaccine 20:3569-3575. https://doi.org/10.1016/S0264-410X(02)00340-7
29. Hodge LM, Simecka JW. 2002. Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease. J Infect Dis 186:290-294. https://doi.org/10.1086/341280
30. Sterner-Kock A, Haider W, Sacchini F, Liljander A, Meens J, Poole J, Guschlbauer M, Heller M, Naessens J, Jores J. 2016. Morphological characterization and immunohistochemical detection of the proinflammatory cytokines IL-1beta, IL-17A, and TNF-alpha in lung lesions associated with contagious bovine pleuropneumonia. Trop Anim Health Prod 48:569-576. https://doi.org/10.1007/s11250-016-0994-9
31. Wang X, Chen X, Tang H, Zhu J, Zhou S, Xu Z, Liu F, Su C. 2016. Increased frequency of Th17 cells in children with Mycoplasma pneumoniae pneumonia. J Clin Lab Anal 30:1214-1219. https://doi.org/10.1002/jcla.22005
32. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123-1132. https://doi.org/10.1038/ni1254
33. Tesmer LA, Lundy SK, Sarkar S, Fox DA. 2008. Th17 cells in human disease. Immunol Rev 223:87-113. https://doi.org/10.1111/j.1600-065X.2008.00628.x
34. Chang SH, Dong C. 2011. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 23:1069-1075. https://doi.org/ 10.1016/j.cellsig.2010.11.022
35. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271-2279. https://doi.org/10.1084/jem.20061308
36. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito JE, Bagby GJ, Nelson S, Charrier K, Peschon JJ, Kolls JK. 2001. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colonystimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194:519-527. https://doi.org/10.1084/jem.194.4.519
37. Gladiator A, Wangler N, Trautwein-Weidner K, LeibundGut-Landmann S. 2013. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J Immunol 190:521-525. https://doi.org/10.4049/jimmunol.1202924
38. Cortez DM, Feldman MD, Mummidi S, Valente AJ, Steffensen B, Vincenti M, Barnes JL, Chandrasekar B. 2007. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK-and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol 293:H3356-H3365. https://doi.org/10.1152/ajpheart.00928.2007
39. Chung DR, Kasper DL, Panzo RJ, Chitnis T, Grusby MJ, Sayegh MH, Tzianabos AO. 2003. CD4+ T cells mediate abscess formation in intraabdominal sepsis by an IL-17-dependent mechanism. J Immunol 170: 1958-1963. https://doi.org/10.4049/jimmunol.170.4.1958
40. Wu Q, Martin RJ, Rino JG, Breed R, Torres RM, Chu HW. 2007. IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection. Microbes Infect 9:78-86. https://doi.org/10.1016/j.micinf.2006.10.012
41. Kurai D, Nakagaki K, Wada H, Saraya T, Kamiya S, Fujioka Y, Nakata K, Takizawa H, Goto H. 2013. Mycoplasma pneumoniae extract induces an IL-17-associated inflammatory reaction in murine lung: implication for mycoplasmal pneumonia. Inflammation 36:285-293. https://doi.org/10.1007/s10753-012-9545-3
42. Cartner SC, Simecka JW, Briles DE, Cassell GH, Lindsey JR. 1996. Resistance to mycoplasmal lung disease in mice is a complex genetic trait. Infect Immun 64:5326-5331
43. Parker RF, Davis JK, Blalock DK, Thorp RB, Simecka JW, Cassell GH. 1987. Pulmonary clearance of Mycoplasma pulmonis in C57BL/6N and C3H/ HeN mice. Infect Immun 55:2631-2635
44. Sieve AN, Meeks KD, Bodhankar S, Lee S, Kolls JK, Simecka JW, Berg RE. 2009. A novel IL-17-dependent mechanism of cross protection: respiratory infection with mycoplasma protects against a secondary listeria infection. Eur J Immunol 39:426-438. https://doi.org/10.1002/ eji.200838726
45. Gaffen SL, Kramer JM, Yu JJ, Shen F. 2006. The IL-17 cytokine family. Vitam Horm 74:255-282. https://doi.org/10.1016/S0083-6729(06)74010-9
46. Song XY, Zhu S, Shi PQ, Liu Y, Shi YF, Levin SD, Qian YC. 2011. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol 12:1151-1158. https:// doi.org/10.1038/ni.2155
47. Rickel EA, Siegel LA, Yoon BR, Rottman JB, Kugler DG, Swart DA, Anders PM, Tocker JE, Comeau MR, Budelsky AL. 2008. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 181:4299-4310. https://doi.org/10.4049/jimmunol.181.6.4299
48. Davis JK, Simecka JW, Williamson JS, Ross SE, Juliana MM, Thorp RB, Cassell GH. 1985. Nonspecific lymphocyte responses in F344 and LEW rats: susceptibility to murine respiratory mycoplasmosis and examination of cellular basis for strain differences. Infect Immun 49:152-158
49. Hickman-Davis JM, Michalek SM, Gibbs-Erwin J, Lindsey JR. 1997. Depletion of alveolar macrophages exacerbates respiratory mycoplasmosis in mycoplasma-resistant C57BL mice but not mycoplasma-susceptible C3H mice. Infect Immun 65:2278-2282
50. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, Wong CH, Schneider E, Dy M, Leite-de-Moraes MC. 2007. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 204:995-1001. https://doi.org/10.1084/jem.20061551
51. Khader SA, Gaffen SL, Kolls JK. 2009. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2:403-411. https://doi.org/10.1038/mi.2009.100
52. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. 2004. IL-17 cytokine family. J Allergy Clin Immunol 114:1265-1273. https://doi.org/ 10.1016/j.jaci.2004.10.019
53. Wakeham J, Wang J, Xing Z. 2000. Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL/6 and BALB/c mice. Infect Immun 68:6946-6953. https://doi.org/10.1128/IAI.68.12.6946-6953.2000
54. Pedraza-Zamora CP, Delgado-Dominguez J, Zamora-Chimal J, Becker I. April 2017. Th17 cells and neutrophils: close collaborators in chronic Leishmania mexicana infections leading to disease severity. Parasite Immunol 39. https://doi.org/10.1111/pim.12420
55. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, Kishihara K, Hara H, Nakae S, Iwakura Y, Matsuzaki G. 2010. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 184:4414-4422. https://doi.org/10.4049/jimmunol.0903332
56. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133-1141. https://doi.org/10.1038/ni1261
57. Jimbo S, Suleman M, Maina T, Prysliak T, Mulongo M, Perez-Casal J. 2017. Effect of Mycoplasma bovis on bovine neutrophils. Vet Immunol Immunopathol 188:27-33. https://doi.org/10.1016/j.vetimm.2017.04.011
58. Howard CJ, Taylor G. 1983. Interaction of mycoplasmas and phagocytes. Yale J Biol Med 56:643-648
59. Zhang YC, Wang HP, Ren JY, Tang XF, Jing Y, Xing DH, Zhao GS, Yao Z, Yang X, Bai H. 2012. IL-17A synergizes with IFN-gamma to upregulate iNOS and NO production and inhibit chlamydial growth. PLoS One 7:e39214. https://doi.org/10.1371/journal.pone.0039214
60. Mao H, Pan F, Guo HX, Bu FF, Xin T, Chen SK, Guo YJ. 2016. Feedback mechanisms between M2 macrophages and Th17 cells in colorectal cancer patients. Tumour Biol 37:12223-12230. https://doi.org/10.1007/ s13277-016-5085-z
61. Nishikawa K, Seo N, Torii M, Ma N, Muraoka D, Tawara I, Masuya M, Tanaka K, Takei Y, Shiku H, Katayama N, Kato T. 2014. Interleukin-17 induces an atypical M2-like macrophage subpopulation that regulates intestinal inflammation. PLoS One 9:e108494. https://doi.org/10.1371/ journal.pone.0108494
62. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE, Jr, Spellberg B. 2009. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5:e1000703. https://doi.org/10.1371/ journal.ppat.1000703
63. Banerjee A, Bhattacharya P, Joshi AB, Ismail N, Dey R, Nakhasi HL. 2016. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines. Cell Immunol 309: 37-41. https://doi.org/10.1016/j.cellimm.2016.07.004
64. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, von Stebut E. 2009. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol 182:3039-3046. https://doi.org/ 10.4049/jimmunol.0713598
65. Woolard MD, Hudig D, Tabor L, Ivey JA, Simecka JW. 2005. NK cells in gamma-interferon-deficient mice suppress lung innate immunity against Mycoplasma spp. Infect Immun 73:6742-6751. https://doi.org/ 10.1128/IAI.73.10.6742-6751.2005
66. Pfutzner H, Sachse K. 1996. Mycoplasma bovis as an agent of mastitis, pneumonia, arthritis and genital disorders in cattle. Rev Sci Tech 15: 1477-1494
67. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB. 2004. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650-659. https://doi.org/10.1002/art.20001
68. Patel DD, Lee DM, Kolbinger F, Antoni C. 2013. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 72(Suppl 2):ii116-123. https://doi.org/10.1136/annrheumdis-2012-202371
69. Liu L, Lu JR, Allan BW, Tang Y, Tetreault J, Chow CK, Barmettler B, Nelson J, Bina H, Huang LH, Wroblewski VJ, Kikly K. 2016. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 9:39-50. https://doi.org/10.2147/JIR.S100940
70. Davidson MK, Lindsey JR, Parker RF, Tully JG, Cassell GH. 1988. Differences in virulence for mice among strains of Mycoplasma pulmonis. Infect Immun 56:2156-2162
71. Davidson MK, Davis JK, Lindsey JR, Cassell GH. 1988. Clearance of different strains of Mycoplasma pulmonis from the respiratory tract of C3H/HeN mice. Infect Immun 56:2163-2168